Therapeutic Asset Ratings

243 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pfizer-Covid-19 Vaccine Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Ppsv23 Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Prevnar 13 Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Prevnar 20 Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Recombinant respiratory syncytial virus pre-fusion F protein antigen Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Shingrix Lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	P4	B (56)
Atezolizumab Lymphoma	Glenmark Specialty S.A.	P2	B (56)
Capecitabine Lymphoma	Huiqiang Huang	P2	B (56)
Ipilimumab Lymphoma	National Cancer Institute (NCI)	P2	B (56)
Isatuximab Lymphoma	Divaya Bhutani	P2	B (56)
Mosunetuzumab Lymphoma	Inhye Ahn	P2	B (56)
Pembrolizumab Lymphoma	Merck Sharp & Dohme LLC	P2	B (56)
Selinexor Lymphoma	Second Affiliated Hospital of Soochow University	P2	B (56)
Zanubrutinib Lymphoma	Inhye Ahn	P2	B (56)
Amdizalisib Lymphoma	Hutchmed	P2	CCC (55)
FALLYPRIDE Lymphoma	National Cancer Institute (NCI)	P2	CCC (55)
Apixaban Lymphoma	Medical University of Gdansk	P3	CCC (54)
Duvelisib Lymphoma	SecuraBio	P3	CCC (54)
NEPENTHE Lymphoma	St. Louis University	P3	CCC (54)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- Lymphoma	National Cancer Institute (NCI)	P2	CCC (54)
Hpc, Cord Blood Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (54)
Nelarabine Lymphoma	University of Chicago	P2	CCC (54)
BMS-986345 Lymphoma	SecuraBio	P3	CCC (53)
Famotidine Lymphoma	Sherief Abd-Elsalam	P3	CCC (52)
Grastofil Lymphoma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (52)

Showing 76 to 100 of 243 assets

PreviousPage 4 of 10Next